Acalabrutinib And Rituximab As First-Line Therapy For Older Patients With Mcl

Acalabrutinib and rituximab as first-line therapy for older patients with MCL

VJHemOnc – Video Journal of Hematology & HemOnc

Treatment approaches for older patients with MCL

VJHemOnc – Video Journal of Hematology & HemOnc

Highlights on first-line treatment of Mantle Cell Lymphoma: Primary results from SHINE

European Society for Medical Oncology (ESMO)

Phase II trial of acalabrutinib, lenalidomide and rituximab in patients with MCL

VJHemOnc – Video Journal of Hematology & HemOnc

Selecting BTK inhibitors for patients with MCL

VJHemOnc – Video Journal of Hematology & HemOnc

Acalabrutinib plus venetoclax and rituximab in MCL & the importance of chemotherapy-free regimens

VJHemOnc – Video Journal of Hematology & HemOnc

Acalabrutinib plus venetoclax and rituximab in the treatment of MCL

VJHemOnc – Video Journal of Hematology & HemOnc

Zanubrutinib plus rituximab in first-line MCL therapy

VJHemOnc – Video Journal of Hematology & HemOnc

BRAWM: bendamustine, rituximab and acalabrutinib for Waldenström’s macroglobulinemia

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Karmali on Treating Older Patients With MCL in the Rituximab Era

Acalabrutinib in combination with bendamustine & rituximab in treatment-naïve or R/R MCL

VJHemOnc – Video Journal of Hematology & HemOnc

Safety and Efficacy Findings for Acalabrutinib Plus Bendamustine and Rituximab in MCL

Rationale for Combining Acalabrutinib With Bendamustine and Rituximab in MCL

Targeted Oncology

Dr. Wang on Addition of Acalabrutinib to Bendamustine/Rituximab in MCL

Dr. Wang on the Toxicity of Ibrutinib, Acalabrutinib, and Zanubrutinib in MCL

Bendamustine/Rituximab as Induction Therapy in MCL

Targeted Oncology

Ibrutnib in Older Patients With Mantle Cell Lymphoma

Targeted Oncology

Rebooting the BTK Inhibitor Sequence in MCL

PeerView Oncology

Acalabrutinib for Treating Mantle Cell Lymphoma

First-Line Treatment for Mantle Cell Lymphoma

Targeted Oncology